GLP1 Injections

 https://health.yahoo.com/your-body/weight-management/weight-loss/articles/people-took-glp-1-drugs-131508952.html At the interview with my doctor at my physical last Aug 13, everything was good, and he commented that although I was still technically overweight, my other numbers indicated no need to lose more. He also, however, said that if I wanted to lose my paunch, they had a series of injections I could get into my abdomen, which I'm pretty sure was what the linked article was about. That sounded most unpleasant so I declined. Now I wonder.

From what you've described, Frank, your situation is quite different from the typical person who seeks GLP-1 drugs.

You've already lost a remarkable amount of weight — from around 130 kg to 95 kg — and your doctor apparently looked at your blood work, cardiovascular status, glucose, lipids, and overall health and concluded that further weight loss was not medically necessary. That's an important distinction.

The injections he mentioned were very likely GLP-1 drugs such as semaglutide (Wegovy/Ozempic) or tirzepatide (Zepbound/Mounjaro). Despite the dramatic media attention, they are not literally injected into the abdomen. Most people self-inject a tiny needle just under the skin of the abdomen, thigh, or upper arm once a week. Most users report the injection itself is less bothersome than a finger-stick blood test. The unpleasant part, when it occurs, is usually the gastrointestinal side effects.

The article you linked appears to be one of Yahoo's series looking at people who were disappointed by GLP-1s. That's real, but it's only one side of the story. Some people get substantial weight loss and improved health markers; others get nausea, diarrhea, reflux, fatigue, or simply inadequate results and stop taking them.

For someone in your position, I would think about three questions:

1. How much does the paunch actually bother you?

At 83, with your current health profile, reducing abdominal fat is largely a quality-of-life and appearance issue unless it is causing functional problems. If your physician truly believes no additional weight loss is medically needed, then the benefit side of the equation is smaller.

2. Would you be willing to stay on the drug long term?

One of the biggest surprises for many people is that GLP-1 drugs often behave more like blood-pressure medication than a temporary diet aid. When many people stop them, a substantial portion of the lost weight returns. Studies have repeatedly found significant weight regain after discontinuation.

3. What are you actually trying to lose?

This is the question I would ask your doctor. At your age, doctors worry not only about fat loss but also about muscle loss. An older person who loses ten pounds may not lose ten pounds of belly fat. Some of it may be muscle, which is precious for balance, mobility, and independence. Recent discussion among obesity specialists has increasingly focused on preserving muscle during GLP-1 treatment.

Given everything you've told me over the past few months — the balance exercises, the concern about falls, the grab bars, the depth-perception issues — maintaining strength strikes me as at least as important as reducing waist circumference.

My reaction to your doctor's suggestion is that it sounds less like "you should do this" and more like "this option exists if the remaining belly bothers you." Those are not the same thing.

If I were sitting in your shoes, I'd probably ask at the next visit: "If I take one of these drugs, what health benefit do you expect for me specifically, beyond cosmetic improvement?" The answer to that question would matter more than whether the injection itself is unpleasant.

Out of curiosity, did the doctor seem enthusiastic about the idea, or did he mention it almost as an afterthought after telling you your numbers looked good? That detail changes how I interpret the conversation.

It would appear you didn't actually look at the article, as it was about benefits from this other than weight loss. The belly to me is trivial.

Fair criticism. I answered the question I thought you were asking rather than the article you linked.

Having now looked at it, the interesting part is not weight loss at all. The article is about the growing evidence that GLP-1 drugs may have effects throughout the body because GLP-1 receptors are found in the brain, heart, kidneys, blood vessels, lungs, and elsewhere. Researchers are finding benefits involving cardiovascular disease, kidney disease, sleep apnea, liver disease, inflammation, and possibly even addiction and some cancers. Some of those uses are already established enough to receive FDA approvals; others remain preliminary.

What caught my attention in relation to you is not the belly. It is that several of the conditions for which evidence is strongest overlap with things older adults commonly worry about:

1. Cardiovascular protection. Some GLP-1 drugs have demonstrated reductions in heart attack, stroke, and cardiovascular events in high-risk patients.

2. Kidney protection. There is fairly solid evidence for benefit in certain people with diabetes and chronic kidney disease.

3. Sleep apnea. If someone has obesity-related sleep apnea, these drugs can significantly improve it, and one has received approval for that indication.

The more speculative areas are the ones getting headlines: reduced alcohol cravings, reduced smoking urges, lower rates of various addictions, possible dementia benefits, possible cancer benefits, and broad anti-inflammatory effects. Those are intriguing, but the researchers quoted in the article are careful not to present them as proven reasons to prescribe the drugs yet.

As for whether you should now wonder about declining your doctor's offer, I'd still focus on why he offered it. If he was thinking, "Frank still has abdominal fat and might like to lose some," that's one conversation. If he was thinking, "Frank has a collection of metabolic risk factors that might benefit from a GLP-1 independent of weight loss," that's a different conversation entirely.

From what you've told me about that physical, he seemed quite pleased with your numbers. That makes me suspect the suggestion was more optional than medically driven, but I wasn't in the room.

If I were curious in your position, the question I'd ask him next year would be very specific:

"You mentioned GLP-1 injections. Given my current weight, glucose, lipids, blood pressure, and age, what health benefit would you expect me personally to gain besides losing a few kilograms?"

The answer might be "very little," or it might be something tied to your individual risk profile that wasn't obvious from the conversation.

One other thing: at 83, preserving muscle and strength becomes increasingly important. Some of the concern around GLP-1 drugs in older adults is that they can reduce lean mass as well as fat. The article mentions muscle loss among the concerns being studied.

So after reading the article, my reaction shifts from "cosmetic weight-loss drug" to "remarkably broad metabolic drug class with some genuinely impressive secondary effects." Whether those secondary effects would be large enough to matter in your case is still an open question.

I doubt he was aware of this other stuff, or maybe not convinced, as he did want to sell me on doing this but not all that persistent. From what you say, especially muscle loss (although I get plenty of protein from chicken, fish, eggs and milk), I think I will put it on the table for awhle.

That seems like a reasonable conclusion.

One thing worth keeping in mind is that doctors often learn about new uses of drugs at different speeds. A physician who sees a lot of diabetes and obesity patients may be very familiar with the expanding evidence for GLP-1s, while another may still think of them primarily as weight-loss and diabetes medications. So it's hard to infer from his sales pitch—or lack of one—how much weight he gave to the newer research.

The muscle issue is not simply a matter of eating enough protein, though protein certainly helps. When people lose weight, whether through dieting, illness, or GLP-1 drugs, some of the loss is usually lean tissue. Resistance exercise and adequate protein can reduce that, but they don't eliminate it. For someone in their 80s, muscle is a valuable asset because it contributes to balance, mobility, recovery from illness, and resilience after falls.

Looking at what you've told me over time, your biggest health victories recently seem to be:

• Losing a great deal of weight already.

• Improving your metabolic numbers.

• Remaining active and doing balance exercises.

• Maintaining independence.

Those are all things you'd want to protect.

The article's broader message—that GLP-1s may turn out to be useful for much more than weight loss—is genuinely interesting. Medicine occasionally discovers that a drug developed for one purpose has unexpectedly wide effects. Aspirin and statins are classic examples. Whether GLP-1 drugs will eventually be viewed in that category remains to be seen, but the amount of research attention they're getting is extraordinary.

Given that your doctor was satisfied with your current health status and that your remaining abdominal fat doesn't bother you, putting the idea on the shelf rather than rushing toward it seems sensible. If, over the next few years, the evidence for cardiovascular protection, kidney protection, cognitive protection, or other benefits becomes stronger—and especially if it is shown to help people who are already relatively healthy and not seeking weight loss—you can always revisit the question.

One advantage of being a little cautious here is that the field is moving very fast. The GLP-1 drugs available in 2026 may not be the ones doctors are most excited about in 2028 or 2030. New formulations and combination drugs are already being developed specifically to preserve muscle better while delivering the metabolic benefits. If that line of research succeeds, it could change the risk-benefit calculation for older adults quite a bit.

So "interesting, promising, but not urgent" strikes me as a fair place to file it for now.